Titan Pharmaceuticals, Inc. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/338b1906-7499-4f87-92d3-e2bf8726c2f6/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-4.6M | 2024-01-01 – 2024-12-31 | evidence 0001829126-25-001934 |
| FY 2023 | $-7.3M | 2023-01-01 – 2023-12-31 | evidence 0001829126-24-002110 |
| FY 2022 | $-10.2M | 2022-01-01 – 2022-12-31 | evidence 0001829126-23-002504 |
| FY 2021 | $-9.4M | 2021-01-01 – 2021-12-31 | evidence 0001410578-22-000518 |
| FY 2020 | $-7.4M | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-044732 |
| FY 2019 | $-7.9M | 2019-01-01 – 2019-12-31 | evidence 0001104659-21-044732 |
| FY 2018 | $-8.3M | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-017459 |
| FY 2017 | $-14.5M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-018448 |
| FY 2016 | $4.3M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-014986 |
| FY 2015 | $-6.8M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-088046 |
| FY 2014 | $-3.5M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-019881 |
| FY 2013 | $-891.0k | 2013-01-01 – 2013-12-31 | evidence 0001144204-14-019329 |
| FY 2012 | $-8.4M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-111045 |
| FY 2011 | $-10.5M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-117326 |
| FY 2010 | $-6.0M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-117326 |
| FY 2009 | $-5.8M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-117326 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Titan Pharmaceuticals, Inc. — all facts · Revenue · Net Income